Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Completed 26Unknown 19Recruiting 14Active not recruiting 8Withdrawn 3Terminated 3Not yet recruiting 2Enrolling by invitation 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 28Carcinoma, Non-Small-Cell Lung 20Triple Negative Breast Neoplasms 9Ovarian Neoplasms 8Lung Neoplasms 8Uterine Cervical Neoplasms 6Adenocarcinoma of Lung 6Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Carcinoma, Ovarian Epithelial 4Stomach Neoplasms 3Recurrence 3Prostatic Neoplasms 3Esophageal Squamous Cell Carcinoma 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Platinum-Refractory Fallopian Tube Carcinoma 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrent High Grade Uterine Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

nimotuzumab 4Paclitaxel 3Surgical Procedures, Operative 2Cisplatin 2sintilimab 1pembrolizumab 1monalizumab 1epacadostat 1Taxes 1TP protocol 1Saline Solution 1Radiation 1Oxaliplatin 1Nimodipine 1Metabolic Networks and Pathways 1Fluorouracil 1Biopsy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Esophageal Squamous Cell Carcinoma × Paclitaxel × Clear all
NCT05312372 2026-02-17

S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

Servier

Phase 1/2 Withdrawn
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04625543 2022-04-26

Neoadjuvant Immunotherapy to ESCC

Qilu Hospital of Shandong University

Phase 2 Withdrawn
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02272699 2021-03-18

Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma

Peking University

Phase 2/3 Withdrawn
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡